Thryv Therapeutics today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to LQT-1213 for the treatment of Long QT Syndrome (LQTS).  LQT-1213 is a novel, first-in-class SGK1 inhibitor specifically designed to treat congenital LQTS.

Thryv Therapeutics announced today its participation in the upcoming 2024 RBC Capital Markets Private Company Virtual Conference. Thryv will attend on Tuesday, October 1st, 2024, and will sit for a fireside chat from 10:30 a.m. to 11:00 a.m. ET.

To schedule one-on-one meetings with the team, please contact admin@thryvtrx.com. 

Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Piper Sandler 35th Annual Healthcare Conference, held from November 28th to November 30th, 2023, at Lotte New York Palace in New York City. Paul Truex, Thryv’s Chairman of the Board & Chief Executive Officer, will present on November 29th from 3:50 to 4:10 PM in Harlem Track, Kennedy 2, 4th floor.

Thryv Therapeutics Inc. is pleased to announce an oral presentation of the effects of SGK-1 inhibition with its potent and selective inhibitor THRV-1268 on atrial fibrillation in an obese-mouse model. This abstract will be presented during the Shocking Results: Basic Science Insights into Arrhythmias session at the American Heart Association Annual Scientific Sessions in Philadelphia, PA.

Thryv Therapeutics Inc. today announced positive results of the WAVE 1 Proof of Concept clinical study evaluating LQT-1213 for the reduction of QTcF in individuals with dofetilide-induced long QT. LQT-1213 is a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase 1 (SGK-1), which is implicated in QTc prolongation.

Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) for THRV-1257. THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E. The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies.

While we await results from our initial proof of efficacy study this summer in Long QT Syndrome, we are able to accelerate a number of pipeline initiatives thanks to this new investment from IQ.

Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers.

Two fireside chats by Mr. Paul F. Truex CEO on Thryv’s progress with the development of a number of highly potent SGK1 inhibitors for all major forms of Long QT Syndrome, atrial fibrillation and resistant cancers.

Results of SGK1 Inhibition in Patient- and Genotype Specific Re-Engineered Heart Cells with Congenital Long QT Syndrome and a model of Drug-Induced QT Prolongation to be presented at the AHA Scientific Sessions 2022 taking place November 5-7, 2022, in Chicago

We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.

LQTT has completed US$19 million Series A financing led by Amplitude Ventures and included new investments from existing investors. We’re advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. that inhibit SGK1.

Amplitude Ventures exceeded their CAD$200M raise target and attracted investment from across the country and internationally. Amplitude is an early seed investor of LQTT.

Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

Research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.

LQT Therapeutics raised up to C$1.8M seed funding led by Fonds de solidarité FTQ and other founding investors. Our aim is to develop a series of preclinical compounds as new treatment options for Long QT Syndrome and other arrhythmias.